Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
AT&T Inc. ( T - Analyst Report ) , the second largest U.S. mobile service provider, increased its share repurchase authorization plan by 300 million additional shares. The buyback represents nearly 5% of the company’s outstanding shares and does not have any expiration date.
This increase will be in addition to the 300 million share buyback plan announced in December 2010. As of June 2012, AT&T repurchased 143.5 million of shares for $4.6 billion and had 156.5 million shares remaining in its previous buyback authorization.
The move reflects the company’s strong commitment to deliver increased returns to its shareholders through attractive dividends and share repurchases. AT&T holds the top position in returning value to shareholders, ahead of its major rivals Verizon Communications Inc. ( VZ - Analyst Report ) and Sprint Nextel Corp. ( S - Analyst Report ) .
AT&T returned approximately $10 billion to its shareholders in the first half of the year including dividends and share buybacks. Last December, AT&T boosted its annual dividend by 2.3% to $1.76 per share, marking the 28th consecutive year of dividend hike. The increasing shareholder returns reveal AT&T’s solid financial position, with a healthy balance sheet and growing free cash flows.
The plan came within a week of the second quarter earnings announcement. AT&T once again delivered an outstanding performance in the quarter with double-digit earnings and operating income growth boosted by a strong wireless segment with record low churn rates and best-ever margins. The company exited the second quarter with net debt-to-adjusted EBITDA ratio of 1.42 times, down from 1.48 times at the end of last quarter.
We are currently maintaining our long-term Neutral recommendation on AT&T. The stock retains a Zacks #3 (Hold) Rank for the short term (1–3 months).
Read the full reports :
Analyst Report on T
Analyst Report on S
Analyst Report on VZ